Sugi Predict

Sugi Predict / Targets / CLK4

CLK4

Dual specificity protein kinase CLK4 · Q9HAZ1 · CLK4 on Sugi Atlas →

266,469 patent compounds predicted against CLK4, 144,785 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL39893 SCHEMBL39893 0.56 9/20
SCHEMBL84029 SCHEMBL84029 0.57 8/20
SCHEMBL39097 SCHEMBL39097 0.58 6/20
SCHEMBL39775 SCHEMBL39775 0.53 6/20
SCHEMBL23608 SCHEMBL23608 0.43 6/20
SCHEMBL46429 SCHEMBL46429 0.52 5/20
SCHEMBL24327 SCHEMBL24327 0.44 5/20
SCHEMBL61346 SCHEMBL61346 0.52 4/20
SCHEMBL90887 SCHEMBL90887 0.49 4/20
SCHEMBL90935 SCHEMBL90935 0.49 4/20
SCHEMBL67822 SCHEMBL67822 0.46 4/20
SCHEMBL10459 SCHEMBL10459 0.44 4/20
Linifanib Linifanib (SCHEMBL93804) 1.00 3/20
Sb-203580 Sb-203580 (SCHEMBL95208) 0.75 3/20
SCHEMBL68193 SCHEMBL68193 0.67 3/20
SCHEMBL68360 SCHEMBL68360 0.67 3/20
SCHEMBL69095 SCHEMBL69095 0.67 3/20
SCHEMBL67345 SCHEMBL67345 0.64 3/20
SCHEMBL67376 SCHEMBL67376 0.64 3/20
SCHEMBL67898 SCHEMBL67898 0.64 3/20

Clinical trials — most relevant to CLK4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Acelarin First Line Randomised Pancreatic Study PHASE2/PHASE3SUSPENDED
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy PHASE2COMPLETED
CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer PHASE2COMPLETED
Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients PHASE2COMPLETED
Everolimus for Cancer With TSC1 or TSC2 Mutation PHASE2COMPLETED
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy PHASE2COMPLETED
A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer PHASE1COMPLETED
A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of Oral ZYGK1 in Healthy Volunteers PHASE1SUSPENDED
Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease. PHASE1COMPLETED
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 PHASE1COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) PHASE1ACTIVE_NOT_RECRUITING
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
A Study of PD1 Combined With Dc-cik in the Treatment of Solid Tumors EARLY_PHASE1UNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation nanCOMPLETED
Protein Intake and Step Reduction in Older Adults nanCOMPLETED
Genomic Analysis of Families With a History of Discordant Cancers nanRECRUITING
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes nanCOMPLETED
Rostock International Parkinson's Disease Study (ROPAD) nanCOMPLETED
Characterization Phenotypic and Genetic Study of the Intestinal Epithelial Dysplasia or Tufting Enteropathy (TE) nanCOMPLETED
Gene-Specific Responses to Exercise in Discordant Twins nanCOMPLETED
Strategy for Management of Patients With Hereditary Cancer Syndromes (HCS) in a Rural Environment nanENROLLING_BY_INVITATION
LRRK2 Activity and Markers of Parkinson's Disease in G2385R Carriers nanCOMPLETED
Natural History, Pathogenesis and Outcome of Melorheostosis A Rare Osteosclerotic Disease nanRECRUITING
Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders nanCOMPLETED
Pharmacogenetics of Metformin Action in PCOS nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CLK4 binder may also engage these)

ProteinNameSimilarity
P22518 — 1.000 P22518 →
O35493 — 1.000 O35493 →
Q63117 — 1.000 Q63117 →
CLK1 Dual specificity protein kinase CLK1 1.000 landscape →
O35492 — 1.000 O35492 →
CLK3 Dual specificity protein kinase CLK3 0.997 landscape →
Q3SX21 — 0.996 Q3SX21 →
CLK2 Dual specificity protein kinase CLK2 0.994 landscape →
O35491 — 0.993 O35491 →
Q5BAE1 — 0.985 Q5BAE1 →
Q53N72 — 0.985 Q53N72 →
Q4FCZ5 — 0.985 Q4FCZ5 →
A2X0M1 — 0.984 A2X0M1 →
Q0E459 — 0.984 Q0E459 →
Q9FGW5 — 0.984 Q9FGW5 →
Q4WYR6 — 0.984 Q4WYR6 →
Q9LV37 — 0.984 Q9LV37 →
Q5VP69 — 0.984 Q5VP69 →
O35832 — 0.983 O35832 →
O35831 — 0.982 O35831 →
O23145 — 0.982 O23145 →
P43289 — 0.982 P43289 →
P43288 — 0.981 P43288 →
Q40518 — 0.981 Q40518 →
Q23357 — 0.981 Q23357 →
P51568 — 0.981 P51568 →
B0VXL7 — 0.981 B0VXL7 →
O13958 — 0.981 O13958 →
Q84M93 — 0.980 Q84M93 →
P43294 — 0.980 P43294 →